Compare DPZ & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DPZ | MDGL |
|---|---|---|
| Founded | 1960 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.2B | 11.5B |
| IPO Year | 2004 | 2005 |
| Metric | DPZ | MDGL |
|---|---|---|
| Price | $317.05 | $454.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 30 | 19 |
| Target Price | $356.48 | ★ $685.78 |
| AVG Volume (30 Days) | ★ 817.1K | 266.9K |
| Earning Date | 10-13-2026 | 11-03-2026 |
| Dividend Yield | ★ 2.56% | N/A |
| EPS Growth | ★ 5.27 | N/A |
| EPS | ★ 12.80 | N/A |
| Revenue | ★ $4,939,994,000.00 | $180,133,000.00 |
| Revenue This Year | $4.99 | $59.57 |
| Revenue Next Year | $1.70 | $38.84 |
| P/E Ratio | $24.32 | ★ N/A |
| Revenue Growth | ★ 4.96 | N/A |
| 52 Week Low | $282.00 | $393.61 |
| 52 Week High | $442.35 | $615.00 |
| Indicator | DPZ | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 56.50 | 34.11 |
| Support Level | $297.56 | $416.21 |
| Resistance Level | $320.57 | $546.29 |
| Average True Range (ATR) | 9.39 | 17.78 |
| MACD | 2.79 | -1.00 |
| Stochastic Oscillator | 95.57 | 16.77 |
Domino's is the world's largest pizza chain, surpassing $20 billion in system sales with over 22,100 stores across more than 90 markets at the end of 2025. Around 33% of its units are in the US. The business is 99% franchised. Domino's operates through three segments: supply chain (60% of revenue), US stores (33%), and international franchises (7%). The firm generates the bulk of its revenue by supplying food to stores in the US and Canada through a vertically integrated network of 25 manufacturing and supply chain facilities, which primarily produce and distribute dough, and by collecting brand royalties and marketing fees from franchisees. Domino's also generates revenue from sales at company-owned stores.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.